Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Sinovac alone -study

09/07/2021 | 03:29am EDT

BEIJING, Sept 7 (Reuters) - A Chinese study https://www.medrxiv.org/content/10.1101/2021.09.03.21263062v1.supplementary-material looking at mixing COVID-19 vaccines showed that receiving a booster shot of CanSino Biologics' vaccine after one or two doses of Sinovac Biotech's vaccine yielded a much stronger antibody response than using the Sinovac shot as a booster.

The study, among the first analyses in China combing different COVID-19 vaccines, comes as the country said it would use booster shots in specific groups amid concerns over vaccines' waning protection over time.

Participants who received a CanSinoBIO booster dose three to six months after a second Sinovac shot showed a 78-fold jump on average in neutralizing antibody levels two weeks later, according to a paper published on Monday before a peer review.

By contrast, those who received a Sinovac booster shot showed a 15.2-fold increase in neutralizing antibody levels, researchers from local disease control authorities, CanSinoBIO and other Chinese institutions said in the paper.

One dose of Sinovac followed by a CanSinoBIO booster at intervals of one or two months led to a 25.7-fold increase in neutralising antibody levels, while two doses of Sinovac induced a 6.2-fold increase.

The study analysed data from about 300 healthy adults aged 18-59.

The study did not assess the boosters' protection against COVID-19 and did not test the neutralising antibody against the more transmissible Delta variant, the paper said.

More than 1.4 billion doses of the Sinovac vaccine have been administered globally, about three quarters of them in China.

China, which has kept local infections under control, has fully vaccinated around 69% of its population as of Sept. 6. It said on Tuesday a total of 2.1 billion doses had been administered as of Monday. (Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Susan Fenton)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CANSINO BIOLOGICS INC. 0.00% 232 End-of-day quote.31.44%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SINOVAC BIOTECH LTD.
10/18SINOVAC BIOTECH : Thailand to cease Sinovac vaccine use when stocks end this month
RE
10/06SINOVAC BIOTECH : Pfizer study to vaccinate whole Brazilian town against COVID-19
RE
10/01SINOVAC BIOTECH : Malaysia approves Sinovac's COVID-19 vaccine for ages 12 to 17
RE
09/29SINOVAC BIOTECH : Rebuffed by Bolsonaro, Brazil medical institute to sell vaccines abroad
RE
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/22SINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
RE
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/09SINOVAC BIOTECH : Says its New Research Shows Third Dose if its COVID-19 Vaccine More Effe..
MT
09/09SINOVAC BIOTECH : New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effecti..
BU
09/08SINOVAC BIOTECH : Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Child..
BU
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | SVA | AGP8696W1045 | MarketScreener
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED4.59%99 388
WUXI BIOLOGICS (CAYMAN) INC.14.69%62 669
SAMSUNG BIOLOGICS CO.,LTD.5.08%47 893
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.16%40 199